The role of her-2/ neu in the carcinogenesis of breast cancer-when and where?;Zur Rolle von Her-2/neu in der Karzinogenese des Mammakarzinoms-wann und wo?

Geburtshilfe und Frauenheilkunde

Volumn 69, Issue 8, 2009, Pages 711-716

  Ruschoff J ^a,b   Nagelmeier, I ^a   Middel, P ^a   Stoss, O ^b  

^a Institut fur Pathologie Nordhessen   (Germany)

^b TARGOS Molecular Pathology GmbH   (Germany)

Author keywords

Carcinogenesis; Early lesions; Her 2 neu

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GROWTH FACTOR RECEPTOR; PROTEIN HER 1; PROTEIN HER 3; UNCLASSIFIED DRUG;

APOPTOSIS; AUTOPHOSPHORYLATION; BREAST CANCER; BREAST CARCINOMA; CANCER GRADING; CANCER GROWTH; CARCINOGENESIS; GENE AMPLIFICATION; GENE OVEREXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION;

EID: 70350474378     PISSN: 00165751     EISSN: 14388804     Source Type: Journal    
DOI: 10.1055/s-0029-1185923     Document Type: Review

References (22)

1. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182
2. Press MF, Bernstein L, Thomas PA et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997; 15: 2894-2904
3. Ross JS, Fletcher JA, Linette GP et al. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 2003; 8: 307-325
4. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792
5. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al., Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-1672
6. Burstein HJ, Polyak K, Wong JS et al. Ductal carcinoma in situ of the breast. N Engl J Med 2004; 350: 1430-1441
7. Bürger H, Böcker W. In: Böcker W, ed. Preneoplasia of the breast. München: Elsevier, Urban & Fischer; 2006: 546
8. Korsching E, Jeffrey SS, Meinerz W et al. Basal carcinoma of the breast revisited: an old entity with new interpretations. J Clin Pathol 2008; 61: 553-560
9. Moulis S, Sgroi DC. Re-evaluating early breast neoplasia. Breast Cancer Research 2008; 10: 302 (doi: 10.1186/bcr1853)
10. Sotiriou C, Wirapati P, Loi S et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006; 98: 262-272.
11. Abdel-Fatah TM, Powe DG, Hodi Z et al. Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: further evidence to support the concept of low nuclear grade breast neoplasia family. Am J Surg Pathol 2008; 32: 513-523
12. van de Vijver MJ. Biological variables and prognosis of DCIS. Breast 2005; 14: 509-519
13. Harari D, Yarden Y. Molecular mechanisms underlying ErbB2/HER2 ac-tionin breast cancer. Oncogene 2000; 19: 6102-6114
14. Korkaya H, Paulson A, Iovino F et al. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 2008; 27: 6120-6130
15. Böcker W, Hungermann D, Weigel S et al. Immunohistochemistry in breast pathology: differential diagnosis of epithelial breast lesions. Pathologe 2009; 30: 13-19
16. Meijnen P, Peterse JL, Antonini N et al. Immunohistochemical categorisation of ductal carcinoma in situ of the breast. Br J Cancer 2008; 98: 137-142
17. van de Vijver MJ. Personal communication.
18. Brand B. In: Böcker W, ed. Preneoplasia of the breast. München: Elsevier, Urban & Fischer; 2006: 556
19. Sergina NV, Rausch M, Wang D et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007; 445: 437-441
20. Lee-Hoeflich ST, Crocker L, Yao E et al. A central role for HER3 in HER2- amplified breast cancer: implications for targeted therapy. Cancer Res 2008; 68: 5878-5887
21. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A et al. An integrative ge-nomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 2008; 68: 6084-6091
22. Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 2008; 10: R25